UBS maintains Envista Holdings at Neutral, raises price target to $29 from $27

UBS kept its Neutral rating on Envista Holdings but raised its price target to $29 from $27, suggesting a 16.2% upside from the Nov 5 close of $24.96. Recent analyst price targets for the company range from $26 to $32.

Original reporting
Published Nov 6, 2026, 12:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Envista Holdings at Neutral, raises price target to $29 from $27 — source image
Decision brief

The 30-second read

$NVSTBullishLow
01

Why it matters

The new $29 target narrows the upside range and could attract short‑term interest.

02

Market read

A modest analyst upgrade for a micro‑cap; limited broader market effect.

03

What to watch

Potential headwinds from supply‑chain constraints are not addressed in the note.

Relevance 5/10Novelty 3/10Timing: today

Background

UBS analyst coverage of Envista Holdings includes recent target ranges of $26‑$32.

Company-level read

Ticker impact

$NVSTBullishMedium confidence
Context

UBS raised its price target on Envista Holdings to $29 from $27, indicating a fresh bullish analyst view.

Expected impact

likely modest buying pressure as investors price in the higher target

Evidence & confidence

Target raise is a new piece of information but the magnitude is small and the company is a micro‑cap, limiting market impact.

Market effects

Minimal; the change reflects a slight shift in sentiment toward the medical‑device sector.

None

None

Counterpoint

The target raise may be premature if upcoming earnings miss expectations.

Key entities

  • Envista Holdings

    Medical‑device manufacturer (ticker NVST).

  • UBS

    Investment bank providing the price target update.

Related articles

$NVSTMedAI 8/10

Envista Announces Pricing of $430 Million of Senior Notes

Envista Holdings Corporation (NYSE: NVST) priced a $430 million offering of 6.250% Senior Notes due 2033 at 99.482% of the principal amount. The offering is expected to close by November 24, 2026. Proceeds will repay a term loan and cover general corporate purposes. J.P. Morgan, BofA Securities, and Wells Fargo Securities are active bookrunners.

$NVSTHighAI 8/10

Envista (NVST) Q3 2026 Earnings Call Transcript

Envista (NVST) reported Q3 2026 core sales growth of 2.7%, adjusted EBITDA growth of 9%, and adjusted EPS growth of 25%. The company raised its full-year 2026 guidance, expecting core growth of 3.75% to 4.25% and adjusted EPS of $1.54 to $1.58. China's market saw a low double-digit contraction due to VBP preparations. The company highlighted product innovations and strong operational performance.